Beran, M <br/><br/>
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Dec 1997 
 - 2377-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Cytarabine--therapeutic use<br/>Diarrhea--chemically induced<br/>Distamycins--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Leukemia--drug therapy<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Leukemia, Myelomonocytic, Acute--drug therapy<br/>Mice<br/>Mice, SCID<br/>Middle Aged<br/>Nausea--chemically induced<br/>Nitrogen Mustard Compounds--administration & dosage<br/>Transplantation, Heterologous<br/>Tumor Cells, Cultured<br/>Vomiting--chemically induced